U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07137637) titled 'HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia' on July 31.
Brief Summary: HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved selectivity, potentially reducing toxicity. Its highly selective and potent inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) may provide additional therapeutic benefits that could enhance treatment efficacy and durability for patients with relapsed or refractory acute myeloid leukemia (RR-AML), further improving clinical outcomes in this population. HPB-092...